Wesbanco Bank Inc. Makes New $945,000 Investment in UroGen Pharma Ltd. (NASDAQ:URGN)

Wesbanco Bank Inc. purchased a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) during the 3rd quarter, HoldingsChannel reports. The fund purchased 74,400 shares of the company’s stock, valued at approximately $945,000.

Several other hedge funds also recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of UroGen Pharma in the third quarter valued at $179,000. Coastal Bridge Advisors LLC raised its position in UroGen Pharma by 4.1% in the second quarter. Coastal Bridge Advisors LLC now owns 38,500 shares of the company’s stock worth $646,000 after acquiring an additional 1,500 shares in the last quarter. Millennium Management LLC lifted its holdings in UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after acquiring an additional 1,119,019 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in UroGen Pharma by 120.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after acquiring an additional 1,337,257 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in shares of UroGen Pharma by 630.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 44,949 shares of the company’s stock worth $754,000 after purchasing an additional 38,799 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Stock Performance

Shares of URGN opened at $12.26 on Wednesday. The company has a 50-day moving average of $13.56 and a two-hundred day moving average of $14.38. The stock has a market cap of $287.55 million, a price-to-earnings ratio of -3.61 and a beta of 1.11. The company has a debt-to-equity ratio of 3.23, a current ratio of 8.15 and a quick ratio of 7.93. UroGen Pharma Ltd. has a one year low of $10.60 and a one year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The company had revenue of $21.85 million for the quarter, compared to analysts’ expectations of $23.69 million. On average, equities research analysts expect that UroGen Pharma Ltd. will post -3.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research note on Tuesday. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a report on Monday. Finally, Guggenheim assumed coverage on UroGen Pharma in a research note on Thursday, August 22nd. They set a “buy” rating and a $40.00 price objective for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, UroGen Pharma has a consensus rating of “Buy” and a consensus price target of $48.38.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.